Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.Blood Cancer Journal|July 5, 2024
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 yearsPhilipp Berning, Mathilde Fekom, Maud Ngoya, et al.Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.Blood|March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in GermanyWolfgang A Bethge, Peter Martus, Michael Schmitt, et al.American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.Blood|January 29, 2021
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHLNorbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.Pageof 10